Page 191 - Read Online

Glinsky Genetic signatures of lethal disease in early stage prostate cancer

Figure 2: GES-based identification of lethal disease in Gleason 6 and 7 prostate cancer patients. Kaplan-Meier survival analysis of the
classification performance of the 98 genes GES in 200 Gleason 6 and 7 prostate cancer patients (A), 83 Gleason 6 patients (B), and 117
Gleason 7 patients (C). Classification threshold 98 genes GES score of 270.43 units was chosen using the training set of 141 prostate
cancer patients and consistently applied in all subsequent validation screens using the Kaplan-Meier survival analysis to stratify the patients
into lethal disease sub-groups (score ≥ 270.43) and moderate/aggressive disease sub-group (score < 270.43). Percent values indicate the
proportion of patients in the lethal disease sub-group. P values indicate the significance of the differences in the numbers of death events
and surviving patients between the groups which was determined using two-sided Fisher’s exact test. GES: gene expression signatures
Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ September 21, 2017 183